Martin Edelman, MD

Professor, Chair, Department of Hematology/Oncology, G. Morris Dorrance Jr. Chair in Medical Oncology, Associate Cancer Center Director for Clinical Research Integration, Chair, Department of Medical Oncology, Lewis Katz School of Medicine at Temple University

Cancer Signaling and Microenvironment (CSM)
Chair, Department of Hematology/ Oncology, Hematology Oncology

https://orcid.org/0000-0002-3752-0726

h-index
h10-index
h5-index

Research activity per year

193 Article
31 Review article
13 Comment/debate
3 Chapter
More

3 results

Filter

2017
Whole-brain radiation in the treatment of brain metastases in ALK-positive non-small-cell lung cancer
Molitoris, J. K., Edelman, M. J., Regine, W. F. & Feigenberg, S. J., Mar 1 2017, In: Journal of Clinical Oncology. 35, 7, p. 809-810 2 p.
Research output: Contribution to journal › Letter › peer-review
3 Scopus citations
2012
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer
Edelman, M. J., Hodgson, L., Wang, X., Kratzke, R. A. & Vokes, E. E., Jun 1 2012, In: Journal of Clinical Oncology. 30, 16, p. 2019-2020 2 p.
Research output: Contribution to journal › Letter › peer-review
22 Scopus citations
2002
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma - Carboplatin and gemcitabine followed by paclitaxel - Author reply: Author's Reply
Edelman, M., Gandara, D., Lara, P. & Lau, D., May 15 2002, In: Cancer. 94, 10, p. 2798-2799 2 p.
Research output: Contribution to journal › Letter › peer-review

Martin Edelman, MD

Research output

Search results

Whole-brain radiation in the treatment of brain metastases in ALK-positive non-small-cell lung cancer

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma - Carboplatin and gemcitabine followed by paclitaxel - Author reply: Author's Reply